These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 23192846)

  • 1. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.
    Banypersad SM; Sado DM; Flett AS; Gibbs SD; Pinney JH; Maestrini V; Cox AT; Fontana M; Whelan CJ; Wechalekar AD; Hawkins PN; Moon JC
    Circ Cardiovasc Imaging; 2013 Jan; 6(1):34-9. PubMed ID: 23192846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
    Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
    J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?
    Cuddy SAM; Bravo PE; Falk RH; El-Sady S; Kijewski MF; Park MA; Ruberg FL; Sanchorawala V; Landau H; Yee AJ; Bianchi G; Di Carli MF; Cheng SC; Jerosch-Herold M; Kwong RY; Liao R; Dorbala S
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1325-1336. PubMed ID: 32417333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping.
    Ioannou A; Patel RK; Martinez-Naharro A; Razvi Y; Porcari A; Hutt DF; Bandera F; Kotecha T; Venneri L; Chacko L; Massa P; Hanger M; Knight D; Manisty C; Moon J; Quarta C; Lachmann H; Whelan C; Kellman P; Hawkins PN; Gillmore JD; Wechelakar A; Fontana M
    JACC Cardiovasc Imaging; 2023 Aug; 16(8):1038-1052. PubMed ID: 37178079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
    Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
    Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial extracellular volume quantification in cardiac amyloidosis: a comparative study between cardiac computed tomography and magnetic resonance imaging.
    Hayashi H; Oda S; Kidoh M; Yamaguchi S; Yoshimura F; Takashio S; Usuku H; Nagayama Y; Nakaura T; Ueda M; Tsujita K; Hirai T
    Eur Radiol; 2024 Feb; 34(2):1016-1025. PubMed ID: 37597032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique.
    White SK; Sado DM; Fontana M; Banypersad SM; Maestrini V; Flett AS; Piechnik SK; Robson MD; Hausenloy DJ; Sheikh AM; Hawkins PN; Moon JC
    JACC Cardiovasc Imaging; 2013 Sep; 6(9):955-62. PubMed ID: 23582361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
    Knight DS; Zumbo G; Barcella W; Steeden JA; Muthurangu V; Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Kotecha T; Francis R; Rezk T; Quarta CC; Whelan CJ; Lachmann HJ; Wechalekar AD; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):823-833. PubMed ID: 29680336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of Hepatic T1-Mapping and Extracellular Volume Quantification on Routine Cardiac Magnetic Resonance Imaging in Patients with Infiltrative and Systemic Disorders.
    Dolan RS; Stillman AE; Davarpanah AH
    Acad Radiol; 2022 Apr; 29 Suppl 4():S100-S109. PubMed ID: 34702675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing cardiac involvement in amyloidosis using cardiovascular magnetic resonance diffusion tensor imaging.
    Gotschy A; von Deuster C; van Gorkum RJH; Gastl M; Vintschger E; Schwotzer R; Flammer AJ; Manka R; Stoeck CT; Kozerke S
    J Cardiovasc Magn Reson; 2019 Sep; 21(1):56. PubMed ID: 31484544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume.
    Miller CA; Naish JH; Bishop P; Coutts G; Clark D; Zhao S; Ray SG; Yonan N; Williams SG; Flett AS; Moon JC; Greiser A; Parker GJ; Schmitt M
    Circ Cardiovasc Imaging; 2013 May; 6(3):373-83. PubMed ID: 23553570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
    Ridouani F; Damy T; Tacher V; Derbel H; Legou F; Sifaoui I; Audureau E; Bodez D; Rahmouni A; Deux JF
    J Cardiovasc Magn Reson; 2018 Aug; 20(1):58. PubMed ID: 30115079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.
    Karamitsos TD; Piechnik SK; Banypersad SM; Fontana M; Ntusi NB; Ferreira VM; Whelan CJ; Myerson SG; Robson MD; Hawkins PN; Neubauer S; Moon JC
    JACC Cardiovasc Imaging; 2013 Apr; 6(4):488-97. PubMed ID: 23498672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
    Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
    Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.
    Syed IS; Glockner JF; Feng D; Araoz PA; Martinez MW; Edwards WD; Gertz MA; Dispenzieri A; Oh JK; Bellavia D; Tajik AJ; Grogan M
    JACC Cardiovasc Imaging; 2010 Feb; 3(2):155-64. PubMed ID: 20159642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR.
    Fontana M; White SK; Banypersad SM; Sado DM; Maestrini V; Flett AS; Piechnik SK; Neubauer S; Roberts N; Moon JC
    J Cardiovasc Magn Reson; 2012 Dec; 14(1):88. PubMed ID: 23272651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
    Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1 mapping and survival in systemic light-chain amyloidosis.
    Banypersad SM; Fontana M; Maestrini V; Sado DM; Captur G; Petrie A; Piechnik SK; Whelan CJ; Herrey AS; Gillmore JD; Lachmann HJ; Wechalekar AD; Hawkins PN; Moon JC
    Eur Heart J; 2015 Jan; 36(4):244-51. PubMed ID: 25411195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging.
    Bandula S; Banypersad SM; Sado D; Flett AS; Punwani S; Taylor SA; Hawkins PN; Moon JC
    Radiology; 2013 Sep; 268(3):858-64. PubMed ID: 23674785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.